An emerging class of orexin-based drugs are on the cusp of disrupting care for sleep disorders — and potentially much more.

Neurons that secrete the neuropeptide orexin help mice decide between exercise and snacking. I n neurobiologist Daria ...

For most of us, getting less than seven hours of sleep translates into grogginess, sluggish thinking, and an overwhelming ...

More information: Insung Park et al, Orexin receptor antagonist increases fat oxidation and suppresses protein catabolism during sleep in humans, iScience (2024). DOI: 10.1016/j.isci.2024.110212 ...

Orexin antagonists, meanwhile – such as Eisai's Dayvigo (lemborexant), Merck & Co's Belsomra (suvorexant) and Idorsia's recently filed daridorexant – have proved effective as treatments for ...

Bial-Portela & Ca SA has identified orexin OX1 receptor antagonists reported to be useful for the treatment of cognitive, sleep, anxiety and eating disorders, depression, obesity, schizophrenia, ...

Idorsia has become the first drugmaker in the EU to claim approval for a drug for chronic insomnia in the dual orexin receptor antagonist class, ahead of rival drugs from Merck & Co and Eisai.

Q4 2024 Management View CEO Richard Pops highlighted 2024 as a transformative year focused on profitability and pipeline development, achieving over $1.5 billion in revenue and $450 million in EBITDA ...